-
Product Insights
CLV/ PBC Group – Gladstone Station Mixed-Use Development – Ontario
Equip yourself with the essential tools needed to make informed and profitable decisions with our CLV/ PBC Group - Gladstone Station Mixed-Use Development - Ontario report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
InterRent REIT/ PBC Group/ Trinity Dev – 900 Albert Street Mixed-Use Development – Ontario
Equip yourself with the essential tools needed to make informed and profitable decisions with our InterRent REIT/ PBC Group/ Trinity Dev - 900 Albert Street Mixed-Use Development - Ontario report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Bezafibrate + Obeticholic Acid) in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Bezafibrate + Obeticholic Acid) in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drug Details: Fixed-dose combination of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – A-3907 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. A-3907 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drug Details: A-3907 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – A-3907 in Liver Diseases
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. A-3907 in Liver Diseases Drug Details: A-3907 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EP-547 in Pruritus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EP-547 in Pruritus Drug Details:EP-547 is under developmant for the treatment of cholestatic pruritus due to primary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EP-547 in Hepatitis B
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EP-547 in Hepatitis B Drug Details:EP-547 is under developmant for the treatment of cholestatic pruritus due to...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EP-547 in Hepatitis C
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EP-547 in Hepatitis C Drug Details:EP-547 is under developmant for the treatment of cholestatic pruritus due to...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EP-547 in Uremic (Renal) Pruritus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EP-547 in Uremic (Renal) Pruritus Drug Details:EP-547 is under developmant for the treatment of cholestatic pruritus due...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABC-008 in T-Cell Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ABC-008 in T-Cell LeukemiaDrug Details:AB-008 is under development for the treatment of inclusion body myositis (IBM),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABC-008 in Inclusion Body Myositis (IBM)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ABC-008 in Inclusion Body Myositis (IBM)Drug Details:AB-008 is under development for the treatment of inclusion body...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elafibranor in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Elafibranor in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drug Details:Elafibranor (GFT-505) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elafibranor in Primary Sclerosing Cholangitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Elafibranor in Primary Sclerosing CholangitisDrug Details:Elafibranor (GFT-505) is under development for the treatment of colitis, non-alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Primary Sclerosing Cholangitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maralixibat Chloride in Primary Sclerosing CholangitisDrug Details:Maralixibat chloride (Livmarli) is an anti-pruritus agent. It is formulted...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Biliary Atresia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maralixibat Chloride in Biliary AtresiaDrug Details:Maralixibat chloride (Livmarli) is an anti-pruritus agent. It is formulted as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Progressive Familial Intrahepatic Cholestasis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maralixibat Chloride in Progressive Familial Intrahepatic CholestasisDrug Details:Maralixibat chloride (Livmarli) is an anti-pruritus agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Difelikefalin in Pruritus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Difelikefalin in Pruritus Drug Details:Difelikefalin Acetate (Korsuva, Kapruvia) is a antipruritic agent. It is formulated as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Difelikefalin in Notalgia Paresthetica
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Difelikefalin in Notalgia ParestheticaDrug Details:Difelikefalin Acetate (Korsuva, Kapruvia) is a antipruritic agent. It is formulated as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Foralumab in Secondary Progressive Multiple Sclerosis (SPMS)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details: Foralumab is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ustekinumab in Type 1 Diabetes (Juvenile Diabetes)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ustekinumab in Type 1 Diabetes (Juvenile Diabetes) Drug Details: Ustekinumab (Stelara, Finlius) is a human monoclonal...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.